Leqembi FDA approval: Prepare your practice with insights from 1,000 older adults about Alzheimer's

The treatment landscape for Alzheimer’s (AD) and other dementias is shifting quickly. With the FDA’s recent full approval of Leqembi (lecanemab) — a new drug targeting early-stage AD that slows disease progression by identifying and attacking beta amyloid proteins in the brain — and expanding data on lifestyle interventions to slow cognitive decline, there is new hope for millions around the world. But to facilitate the timely intervention required to optimize clinical options and outcomes, providers must spot signs of cognitive impairment as early as possible. Patient partnership is critical to the success of both prevention and early detection efforts.

But how much do older adults know about brain health? How open are they to lifestyle changes and cognitive testing? And how would a diagnosis impact how they live their lives? This report offers insights from a survey of 1,000 representative US adults 65+, revealing their perspectives and preferences – as well as key gaps in the current state of cognitive care.

Download the report to learn:

• Why 92% of older adults would prefer to detect Alzheimer’s before symptoms arise
• What 60% of older adults say they would do upon hearing of a new drug being approved
• Which modifiable risk factors over 50% of older adults don’t know about

Complete the form on this page for complimentary access to the whitepaper.